[Principles and perspectives of primary biliary cirrhosis therapy]

Eksp Klin Gastroenterol. 2012:(3):90-5.
[Article in Russian]

Abstract

A survey of existing methods of pathogenetic and symptomatic treatment of primary biliary cirrhosis has been made and it has reviewed prospective directions of its therapy. Is also presents a retrospective analysis of our own data of S-adenosylmethionine (Heptral) in 27 patients PBC receiving UDCA basic therapy. In its application intravenously of 400 mg 2 times daily for 3 weeks showed a reduction in the severity of pruritus, assessed by visual analogue scale, a subjective decrease fatigability and a decrease level of serum bilirubin.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / therapeutic use
  • Fatigue / drug therapy
  • Fatigue / etiology
  • Glucocorticoids / administration & dosage
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / therapeutic use
  • Liver Cirrhosis, Biliary / complications
  • Liver Cirrhosis, Biliary / drug therapy*
  • Practice Guidelines as Topic
  • Pruritus / drug therapy
  • Pruritus / etiology
  • Receptors, Cytoplasmic and Nuclear / agonists
  • S-Adenosylmethionine / administration & dosage
  • S-Adenosylmethionine / therapeutic use
  • Treatment Outcome
  • Ursodeoxycholic Acid / administration & dosage
  • Ursodeoxycholic Acid / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Glucocorticoids
  • Immunosuppressive Agents
  • Receptors, Cytoplasmic and Nuclear
  • Ursodeoxycholic Acid
  • S-Adenosylmethionine